Drug and alcohol dependence
October 1, 2010
Matthew J Baggott, Earth Erowid, Fire Erowid et al.
78 citations
A survey of 500 individuals who had used Salvia divinorum found that 92.6% typically smoked or vaporized the plant, with acute effects lasting about 14 minutes on average. Most participants (80.6%) said they would use it again, and 38.4% described the experience as unique. On at least one occasion, 25.8% reported persisting positive effects lasting 24 hours or more, often an increased sense of well-being, while 4.4% reported persisting negative effects, most commonly anxiety. These findings suggest that Salvia divinorum may produce subacute improvements in mood, which is unusual for a non-medically used drug.
Matthew J Baggott
50 citations
After a 40-year pause, researchers are again asking whether psychedelics can boost creativity. This critical review examines the conceptual challenges in studying psychedelic-induced creativity, summarizing limited evidence and proposing two broader frameworks. Key challenges include separating creativity from other drug effects that might be mistaken for it and developing operational measures to quantify it. The article reviews major studies, including a reanalysis of raw data from one study. Results are modest and inconclusive but consistent with reports that psychedelics produce unusual or novel thoughts. Given the lack of robust changes in creativity measures, creativity may be too specific a construct to capture the beneficial cognitive changes users report. Feelings of creativity may stem from a more general effect, such as altered mental representations or changes in Bayesian inference.
Psychopharmacology
April 1, 2011
John E Mendelson, Jeremy R Coyle, Juan Carlos Lopez et al.
40 citations
Salvinorin A (SA), the psychoactive compound in the hallucinogenic plant Salvia divinorum, was administered sublingually at doses up to 4 mg to eight experienced users in a placebo-controlled ascending-dose study. No dose produced significantly greater physiological or subjective effects than placebo, and the effects did not resemble those of smoked Salvia divinorum. SA was detectable in plasma and urine but mostly below the reliable quantification limit of 0.5 ng/mL. The results suggest that sublingual bioavailability of SA is low, indicating that higher doses, alternate formulations, or other routes of administration are needed to study its effects in humans.
The Journal of pharmacology and experimental therapeutics
September 18, 2024
Candace B Johnson, Donna Walther, Matthew J Baggott et al.
5 citations
MDMA is effective as a treatment for PTSD but carries cardiovascular and neurological risks. Researchers tested two new compounds, 5-MABB and 6-MABB, in rat brain tissue and in live rats trained to recognize MDMA. The S isomers of both compounds released serotonin, norepinephrine, and dopamine, similar to MDMA. The R isomers released serotonin and partially released norepinephrine but not dopamine. All compounds caused rats to respond as if they had received MDMA, with effects increasing with dose. The R isomers were less potent behaviorally. The findings suggest the aminoalkyl benzofuran structure is a promising starting point for developing safer MDMA-like drugs.
BMJ open
May 11, 2026
Julia Colcott, Alexandre A Guerin, Olivia Carter et al.
A new tool, the MDMA-Assisted Psychotherapy Side Effects Tool (M-SET), was developed to systematically capture side effects during MDMA-assisted psychotherapy. Experts in MDMA-AP and neuropsychopharmacology participated in a two-round online Delphi process to refine a list of 165 items across four questionnaires covering screening, baseline, medication session days, and follow-up. The tool aims to improve safety monitoring and build a more robust evidence base on the tolerability of MDMA-AP for research and clinical use.